MedTrace Logo

Study of PNT2258 for Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT01733238 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2023-06-22

Study results available
· View outcomes & findings →

Summary

This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. It study is a multi-center, nonrandomized, open-label, pilot Phase II investigation of PNT2258 to characterize anti-tumor activity and collect safety data on patients with relapsed or refractory lymphoma.

Conditions

  • Lymphoma, Non-Hodgkin's

Interventions

DRUG

PNT2258

Sponsors & Collaborators

  • Sierra Oncology LLC - a GSK company

    lead INDUSTRY

Principal Investigators

  • Barbara Klencke, M.D. · Sierra Oncology LLC - a GSK company

  • Ayad Al-Katib, MD · St. John Hospital and Medical Center, Van Elslander Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2016-08-31
Completion
2016-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01733238 on ClinicalTrials.gov